Atea

Atea reported its highest quarterly profit in company history for Q1 2026: net profit rose 140% to NOK 389m on a gross revenue of NOK 14.8bn and net sales of NOK 9.7bn. Drivers were primarily strong hardware sales (+18.9% to NOK 6.8bn) and a one-off gain of NOK 152m from the partial sale of the stake in AppXite SIA; adjusted EBIT was NOK 324m (+15.4% y/y). All geographic markets grew, led by Norway and the Baltics, while the company maintains a strong balance sheet and negative net debt. Atea expects further revenue and EBIT growth but warns of supply bottlenecks and higher unit prices for hardware as near-term uncertainties. » More on de.investing.com

Atea reported a 35.7% increase in net profit for Q4 2025 to NOK 333 million on gross revenue of NOK 17.8 billion; EBIT before restructuring rose 23.7% to NOK 488 million. For the full year 2025, gross revenue (NOK 60.2 billion) and net profit (NOK 878 million) rose notably, and EBIT grew by 15.4%. The company secured several large contracts, including a framework agreement with NATO for workplace devices, and proposes a dividend of NOK 7.50 per share. Atea expects revenue growth of 5–7% for 2026 and warns of industry-wide component shortages, but says it is well positioned thanks to a strong balance sheet and partnerships. » More on de.investing.com

Atea reports Q2 2025 gross revenue of NOK 16.8bn (+14.4%), IFRS revenue of NOK 9.1bn (+9.1%), EBIT of NOK 268m (+10.4%) and net profit of NOK 157m (+13.3%). Strong growth was driven mainly by software (+19.6%) and Denmark (+27.1%), while Finland saw declines. Operating cash flow was -NOK 111m, weighed down by higher inventories of school PCs; debt remains very low at NOK 440m with a net/debt-to-EBITDA ratio of 0.2. Atea sees further potential in defense, cybersecurity and AI (including strong Microsoft Copilot sales) and confirms its 2025 outlook of NOK 57–60bn gross revenue and NOK 1,330–1,450m EBIT. » More on de.investing.com

Atea Pharmaceuticals presented at the Morgan Stanley Global Healthcare Conference its plan to advance an eight-week HCV regimen with bemnifosbuvir and ruzasvir. The company reported promising trial data, a favorable interaction profile, and liquidity of $379 million, which it says will fund operations through 2027. Two phase-3 studies (CBYOND, C4WRD) are ongoing; results are expected by the end of 2026, and Atea is seeking partnerships outside the U.S. Remaining challenges include patient identification and market competition; patent protection extends until 2042. » More on de.investing.com

Atea Pharmaceuticals is advancing its fixed-dose combination of Bemnifosbuvir and Ruzasvir with the global phase 3 studies C-BEYOND and C-FORWARD, supported by phase 2 data showing up to 99% SVR12 in adherent patients without cirrhosis. The company reported a net loss of $37.2 million for Q2 2025 with cash and equivalents of $379.7 million, expects a cash runway through 2027, and has initiated a share repurchase program of up to $25 million. In addition, the board of directors was expanded to include Dr. Howard H. Berman, and market research indicates strong prescriber preference for the regimen. » More on de.investing.com